56720 Federal Register / Vol. 70, No. 187 / Wednesday, September 28, 2005 / Notices 

[FR Doc. 05–19339 Filed 9–27–05; 8:45 am] 

BILLING CODE 4160–01–C 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[FDA 225–05–3000] 

Memorandum of Understanding 

Between the Food and Drug 

Administration and the National 

Library of Medicine 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is providing 

notice of a memorandum of 

understanding (MOU) between the Food 

and Drug Administration and the 

National Library of Medicine (NLM). 

The purpose of this MOU is to assign 

responsibilities to FDA’s Center for Drug 

Evaluation and Research (CDER) and 

NLM for the distribution of product 

labeling. 

DATES: The agreement became effective 

July 6, 2005, and supplements the 

agreement signed and dated November 

21, 2001, and December 3, 2001, by 

NLM and CDER representatives, 

respectively. 

FOR FURTHER INFORMATION CONTACT: 

For FDA: Lisa Stockbridge, Food and 

Drug Administration (HFD–140), 

5600 Fishers Lane, Rockville, MD 

20857, 301–827–7761; or Catherine 

Miller, Food and Drug 

Administration (HFD–140), 5600 

Fishers Lane, Rockville, MD 20857, 

301–827–7772. 

For NLM: Simon Liu, Bldg. 38A, rm. 

2N221, 8600 Rockville Pike, 

Bethesda, MD 20894, 301–402–

1698; or Stuart Nelson, Bldg. 38A, 

rm. B2E17, 8600 Rockville Pike, 

Bethesda, MD 20894, 301–496–

1495. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 20.108(c), 

which states that all written agreements 

and MOU’s between FDA and others 

shall be published in the Federal 

Register, the agency is publishing notice 

of this MOU. 

Dated: September 20, 2005. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

BILLING CODE 4160–01–S 


EN28SE05.038</GPH>
Federal Register / Vol. 70, No. 187 / Wednesday, September 28, 2005 / Notices 56721 


EN28SE05.039</GPH>
56722 Federal Register / Vol. 70, No. 187 / Wednesday, September 28, 2005 / Notices 


EN28SE05.040</GPH>
Federal Register / Vol. 70, No. 187 / Wednesday, September 28, 2005 / Notices 56723 

[FR Doc. 05–19340 Filed 9–27–05; 8:45 am] 

BILLING CODE 4160–01–C 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Committee on Heritable 

Disorders and Genetic Diseases in 

Newborns and Children; Notice of 

Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), notice is hereby given 

of the following meeting: 

Name: Advisory Committee on Heritable 

Disorders and Genetic Diseases in Newborns 

and Children (ACHDGDNC). 

Dates and Times: October 20, 2005, 9 a.m. 

to 5 p.m.; October 21, 2005, 9 a.m. to 3 p.m. 

Place: Ronald Reagan Building and 

International Trade Center, 1300 

Pennsylvania Avenue, NW., Washington, DC 

20004. 

Status: The meeting will be open to the 

public with attendance limited to space 

availability. 

Purpose: The Advisory Committee 

provides advice and recommendations 

concerning the grants and projects authorized 

under the Heritable Disorders Program and 

technical information to develop policies and 

priorities for this program. The Heritable 

Disorders Program was established to 

enhance the ability of State and local health 

agencies to provide for newborn and child 

screening, counseling and health care 

services for newborns and children having or 

at risk for heritable disorders. The Committee 

was established specifically to advise and 

guide the Secretary regarding the most 

appropriate application of universal newborn 

screening tests, technologies, policies, 

guidelines and programs for effectively 

reducing morbidity and mortality in 

newborns and children having or at risk for 

heritable disorders. 

Agenda: The first day will be devoted to 

presentations on and a discussion of the 

decision-making methodology of the 

Committee and an update of the current 

status of State specific issues. The second 

day will include meetings and reports from 

the Committee’s subcommittees on laboratory 

standards and procedures, follow-up and 

treatment and education and training. 

Proposed agenda items are subject to 

change. 

Public Comments: Time will be provided 

each day for public comment. Individuals 

who wish to provide public comment or who 

plan to attend the meeting and need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should notify the 

ACHDGDNC Executive Secretary, Michele A. 

Lloyd-Puryear, M.D., Ph.D. (contact 

information provided below). 

Contact Person: Anyone interested in 

obtaining a roster of members or other 

relevant information should write or contact 

Michele A. Lloyd-Puryear, M.D., Ph.D., 

Maternal and Child Health Bureau, Health 

Resources and Services Administration, 

Room 18A–19, Parklawn Building, 5600 

Fishers Lane, Rockville, Maryland 20857, 

Telephone (301) 443–1080. Information on 

the Advisory Committee is available at http:// 

mchb.hrsa.gov/programs/genetics/committee. 

Dated: September 20, 2005. 

Tina M. Cheatham, 

Director, Division of Policy Review and 

Coordination. 

[FR Doc. 05–19295 Filed 9–27–05; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Director’s Council of Public 

Representatives. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Director’s Council of 

Public Representatives. 

Date: October 25, 2005. 

Time: 8:30 a.m. to 3 p.m. 

Agenda: Among the topics proposed for 

discussion are: (1) NIH Director’s update; (2) 

COPR workgroup reports; (3) public 

perspective on the NIH Roadmap; (4) updates 

on the NIH Re-authorization and the Office 

of Portfolio Analysis and Strategic Initiatives; 

(5) NIH response to COPR’s Public Trust 

Report; and (6) discussion and public 

comment. 

Place: National Institutes of Health, 

Building 31, Conference Room 6, 9000 

Rockville Pike, Bethesda, MD 20892. 

Contact Person: Jennifer E. Gorman Vetter, 

NIH Public Liaison/COPR Coordinator, Office 

of Communications and Public Liaison, 

Office of the Director, National Institutes of 

Health, 9000 Rockville Pike, Building 1, 

Room 344, Bethesda, MD 20892. (301) 435–

4448. gormanj@od.nih.gov. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 


EN28SE05.041</GPH>